Radiofrequency ablation therapy under contrast-enhanced harmonic imaging guidance for recurrence after local ablation therapy for hepatocellular carcinoma: A randomized controlled study
Masatoshi Kudo(Kindai University), Mikio Shiomi, Chikara Ogawa, Yasunori Minami, Masayuki Kitano(Wakayama Medical University), Shigenaga Matsui, Emi Ishikawa(Kyowa Chemical Industry (Japan)), Yoichiro Suetomi, Ryosuke Nakaoka, Nobuhiro Fukuda, Toshihiko Kawasaki(Kindai University), Hobyung Chung(Kindai University)
Cited by 0
Related Papers
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
|Journal of Clinical Oncology|2019|1.8k
Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma
|NEJM Evidence|2022|1.4k
Global patterns of hepatocellular carcinoma management from diagnosis to death: the <scp>BRIDGE</scp> Study
|Liver International|2015|1.3k